Raygene

Zhejiang Raygene Pharmaceuticals Co., Ltd ("Raygene") focuses on oncology drug development with at least one small molecule drug candidate (tirapazamine) currently in Phase II/III clinical trials targeting hepatocellular carcinoma via inhibition of topoisomerase II[1]. Another program involving a bispecific monoclonal antibody targeting CTLA4 x PDL1 was discontinued after being investigated for colon cancer liver metastases[1]. The company collaborates with Alphamab Oncology to evaluate combination therapies involving immune checkpoint inhibitors such as KN046 plus RG001 for advanced cancers including HCC and CRC metastases[2].

There are no reports of commercial-stage products yet, nor any evidence that the company operates as a platform technology provider rather than an oncology-focused biopharmaceutical developer focused on small molecules and bispecific antibodies through collaborations.[1][2]